You’re in the thick of week two of negotiations on a term sheet with a potential investor and you can’t help but wonder why you’re spending so much time on a document that has.
Several brokerages have updated their recommendations and price targets on shares of Altimmune (NASDAQ: ALT) in the last few weeks: 5/20/2022 – Altimmune was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.50 price target on the stock. According to Zacks, “Altimmune, Inc. is […]
The pharmaceutical and biotechnology industries are expected to witness a significant growth, owing to the demand for vaccine and treatment drugs for COVID-19.